Evoke Pharma PE Ratio 2012-2024 | EVOK

Current and historical p/e ratio for Evoke Pharma (EVOK) from 2012 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Evoke Pharma PE ratio as of November 01, 2024 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Evoke Pharma PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2024-10-31 5.85 0.00
2024-06-30 6.35 $-16.18 0.00
2024-03-31 7.32 $-21.97 0.00
2023-12-31 12.60 $-27.97 0.00
2023-09-30 16.56 $-27.25 0.00
2023-06-30 19.80 $-28.33 0.00
2023-03-31 22.80 $-30.13 0.00
2022-12-31 32.16 $-32.18 0.00
2022-09-30 22.44 $-33.02 0.00
2022-06-30 38.88 $-34.46 0.00
2022-03-31 71.28 $-36.03 0.00
2021-12-31 79.20 $-37.47 0.00
2021-09-30 187.20 $-43.23 0.00
2021-06-30 197.28 $-46.12 0.00
2021-03-31 263.52 $-76.38 0.00
2020-12-31 371.52 $-74.94 0.00
2020-09-30 675.36 $-70.62 0.00
2020-06-30 509.76 $-69.17 0.00
2020-03-31 167.04 $-41.79 0.00
2019-12-31 233.28 $-47.56 0.00
2019-09-30 123.84 $-53.32 0.00
2019-06-30 90.00 $-56.21 0.00
2019-03-31 216.00 $-63.41 0.00
2018-12-31 357.12 $-66.29 0.00
2018-09-30 429.12 $-61.97 0.00
2018-06-30 360.00 $-98.00 0.00
2018-03-31 299.52 $-105.20 0.00
2017-12-31 325.44 $-139.79 0.00
2017-09-30 480.96 $-147.00 0.00
2017-06-30 368.44 $-139.79 0.00
2017-03-31 446.40 $-171.50 0.00
2016-12-31 290.88 $-183.03 0.00
2016-09-30 325.44 $-219.06 0.00
2016-06-30 986.40 $-237.79 0.00
2016-03-31 732.96 $-253.64 0.00
2015-12-31 475.20 $-272.38 0.00
2015-09-30 419.04 $-288.23 0.00
2015-06-30 753.12 $-318.50 0.00
2015-03-31 1015.20 $-328.58 0.00
2014-12-31 849.60 $-315.61 0.00
2014-09-30 791.93 $-285.35 0.00
2014-06-30 1164.96 $-253.64 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.005B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Teligent (TLGT) United States $0.000B 0.00